<DOC>
	<DOC>NCT01784055</DOC>
	<brief_summary>To monitor the long-term performance of the CE Marked NeoChord Artificial Chordae Delivery System</brief_summary>
	<brief_title>NeoChord TACT Post-Market Surveillance Registry</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Grade 3+ or 4+ mitral valve regurgitation Heavily calcified valves Valvular retraction with severely reduced mobility Active bacterial endocarditis Complex mechanism of MR (leaflet perforation, etc.) Significant tethering of leaflets Inflammatory valve disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>NeoChord</keyword>
	<keyword>DS1000</keyword>
	<keyword>Mitral Valve</keyword>
	<keyword>Mitral Valve Regurgitation</keyword>
	<keyword>MR</keyword>
	<keyword>Mitral Valve Repair</keyword>
	<keyword>Mitral Valve Prolapse</keyword>
	<keyword>Artificial Chordae</keyword>
</DOC>